Direct Transcriptional Targets of Sex Steroid Hormones in Bone

Susan A. Krum*

Department of Orthopaedic Surgery, UCLA Orthopaedic Hospital, David Geffen School of Medicine at UCLA, Los Angeles, California

ABSTRACT

The sex steroid hormones, androgens and estrogens, via their respective nuclear receptors, regulate bone mineral density in humans and mice. Very little is known about the direct targets of the androgen and estrogen receptors in bone cells. First, models of hormone and receptor deficiency in mouse and human bone are discussed. This review then focuses on the direct targets of the receptors in osteoblasts and osteoclasts. A direct target of a NR is defined here as a gene that is regulated by NR binding to the DNA (either through DNA binding or association with a DNA binding protein) at an enhancer or promoter of that gene. The experimental evidence that illustrates androgen and estrogen gene regulation in osteoblasts and osteoclasts will be summarized and compared with the phenotype of the hormones in vivo. J. Cell. Biochem. 112: 401–408, 2011. © 2011 Wiley-Liss, Inc.

KEY WORDS: ESTROGEN; ANDROGEN; BONE; TRANSCRIPTION; STEROID HORMONES

Osteoporosis is a disease characterized by low bone mass due to increased osteoclast activity, and/or decreased osteoblast activity, which leads to an increased risk of fractures. The disease is multi-factorial and low calcium intake, low vitamin D levels and low sex steroid hormone levels are correlated with the disease. Over 10 million people in the United States have osteoporosis and an additional 33.6 million individuals in the US have osteopenia, or low bone mass, that could lead to osteoporosis. Albright et al. [1940] described postmenopausal osteoporosis and proposed that it was due to estrogen deficiency. We now know that both estrogens and androgens are important in the development of bone and maintenance of bone mineral density throughout life.

The sex steroid hormones bind to their cognate steroid hormone nuclear receptors (NRs) to activate transcription of target genes. Estrogens bind to estrogen receptors (ERα and ERβ) and androgens bind to the androgen receptor (AR). Recently, 17β-estradiol (E2) has also been shown to bind to GPR30 to regulate intracellular calcium [Revankar et al., 2005]. Estrogen responsive genes are best-studied in breast cancers and androgen responsive genes are likewise best-studied in prostate cancers; however, the hormone responsive genes in the bone are relatively unknown. ERα, ERβ and AR have each been detected by several methods in both osteoblasts and osteoclasts [Bord et al., 2001; Braidman et al., 2001], but very little is known about their mechanism of action. In this review the genes directly regulated by estrogens and androgens will be described.

GENETIC MODELS OF ERα IN BONE

Estrogens are important in the development of bone in both mice and humans, as evidenced by genetic mouse models and case reports of human mutations. A man with a mutation in ERα had a lack of full bone maturation with a failure of epiphyseal closure and osteoporosis at age 28 [Smith et al., 1994]. Genetic mouse models have demonstrated that both ERs are important for proper bone mineral density. Female and male ERα null mice (ERαKO) have a decrease in cortical bone mineral density, whereas ERβ knockout (ERβKO) mice have normal cortical and cancellous bone mineral density. Mice without either ERα or ERβ (ERαβKO) have both decreased cortical and decreased cancellous bone mineral density, suggesting that ERα and ERβ can replace each other in cancellous bone, but they also have distinct roles [Windahl et al., 2002].

Because of the interaction between the many tissues in which ERα plays a role, ERα was specifically knocked out in osteoclasts (ERα$^{\Delta Oc/\Delta Oc}$) using a cathepsin K-cre recombinase [Nakamura et al., 2007]. The female ERα$^{\Delta Oc/\Delta Oc}$ mice have a decrease in trabecular bone, but not in cortical bone, as do the ERαKO mice. The molecular

mechanism explaining the difference in phenotype between the ERαKO and the ERα$^{ΔOc/ΔOc}$ bones remains to be determined. Confirming the results of Nakamura et al., Martin-Millan et al. [2010] knocked out ERα in osteoclast precursors using the promoter of lysozyme M (LysM); the ERα$^{LysM−/−}$ mice also have a decrease in trabecular bone mineral density. An osteoblast-specific ERαKO mouse has not been generated, but would provide valuable information to determine the role of ERα (vs. ERβ) specifically in osteoblasts (vs. osteoclasts and other cell types).

To differentiate between classical and non-classical/non-genomic ERα signaling, ERαKO mice were crossed to mice with a mutant ERα allele (a two amino acid substitution (E207A/G208A) in the first zinc finger of the DNA binding domain) [Syed et al., 2005]. The mutant ERα cannot bind to an ERE and are thus named Non-classical ER knock-in (NERKI) mice. The ERα$^{-/NERKI}$ mice have a decrease in cortical, but not trabecular bone, as do ERαKO mice. However, ovariectomized ERα$^{-/NERKI}$ mice *gained* bone, in contrast to wildtype mice that have a decrease in bone after ovariectomy. The authors of these studies suggest that there is a balance between classical and non-classical ERα signaling in osteoblasts [Syed et al., 2005].

PROTECTIVE EFFECTS OF ESTROGEN IN BONE

Loss of estrogens results in increased bone turnover, with both increased osteoclast activity and osteoblast activity [Riggs, 2000]. The protective effects of estrogens on bone are through several mechanisms. Estrogens repress osteoclastogenic cytokine production from immune cells [Weitzmann and Pacifici, 2006], increase osteoblast proliferation, decrease osteoblast and osteocyte apoptosis [Kousteni et al., 2002] and induce osteoclast apoptosis [Kameda et al., 1997]. A decrease in estrogen levels during menopause leads to a decrease in both cortical bone mineral density and cancellous bone mineral density. Similarly, ovariectomy in mice also leads to a decrease in both cortical and cancellous bone mineral density. In 2002 the Women's Health Initiative (WHI) showed that estrogen supplementation, either with or without progesterone as part of hormone replacement therapy (HRT), prevents bone fractures. However, the routine use of HRT has diminished significantly due to other results of the WHI suggesting an increased risk of breast cancer, heart disease and stroke in women taking HRT.

The effects of estrogens on osteoblasts are confusing. E2 has been shown to increase osteoblast proliferation [Scheven et al., 1992], have no proliferative effect [Keeting et al., 1991], or to decrease osteoblast proliferation. Jilka et al. [1998] have demonstrated that the number of osteoblast progenitors increases after ovariectomy. Thus, estrogens may suppress the self-renewal of immature osteoblasts. The reports of the effects of E2 on osteoblast differentiation are also mixed [Robinson et al., 1997]. Ovariectomy leads to an increase in osteoblast apoptosis; therefore it is thought that estrogens protect against osteoblast cell death. Indeed, in osteoblasts and osteocytes E2 prevents DNA damage-induced apoptosis. E2 leads to rapid phosphorylation of the Src/Shc/ERK pathway that blocks apoptosis [Kousteni et al., 2001]. The contradictory effects of estrogens on osteoblasts may depend on the source of the osteoblasts (human vs. mouse, calvarial vs. MSC-derived, young vs. old cells), amount of differentiation, amount of ERα due to over-expression, normal cells versus osteosarcoma cells and other factors.

Estrogens have been shown to induce apoptosis in osteoclasts [Kameda et al., 1997; Kousteni et al., 2002] and in contrast, ovariectomy of mice leads to an increase in the number of osteoclasts. Kousteni et al. [2001] suggested that apoptosis in osteoclasts was induced via a non-genomic pathway. This study used estren (4-estren-3,17-diol), which is an estrogen receptor agonist that was thought to only have non-genomic activity. However, recent papers have shown that estren does have transcriptional effects [Hewitt et al., 2006]. Furthermore, estren is thought to activate the androgen receptor. While non-genomic signaling may contribute to apoptosis of osteoclasts, this is not the sole mechanism of action (see the regulation of FasL described below).

Estrogens also regulate bone through the immune system. Menopausal women have increased serum levels of the osteoclastogenic cytokines IL-1, IL-6, IL-7, TNFα, and M-CSF. The major sources of the cytokines are monocytes, macrophages, T-cells and stromal cells, although the cells in which estrogens regulate cytokines are not conclusively identified [reviewed in Weitzmann and Pacifici, 2006].

DIRECT TARGETS OF STEROID HORMONES

Upon binding to ligand (i.e., testosterone or estradiol), NRs are translocated to the nucleus where they bind to enhancers or promoters to regulate a variety of tissue-specific and ligand-specific genes. The "classical" ERE is a 13 base pair inverted palindromic sequence−GGTCANNNTGACC and AR binds to the "classical" ARE: AGAACAnnnTGTTCT [Verrijdt et al., 2003]. In addition, ERα can indirectly activate "non-classical" transcription by binding to other DNA binding proteins such as Sp1 and AP-1 family members (e.g., c-fos or c-jun) [Castro-Rivera et al., 2001]. Finally, ERα can regulate "non-genomic" signaling in which instead of ERα entering the nucleus to activate transcription, ERα activates phosphorylation cascades such as the MAP kinase pathway [Levin, 2005]. AR has also been shown to activate non-genomic signaling [Foradori et al., 2008].

A direct target of a NR is defined here as a gene that is regulated by NR binding to the DNA (either through DNA binding or association with a DNA binding protein) at an enhancer or promoter of that gene. Therefore, experimental evidence to demonstrate DNA binding (i.e., chromatin immunoprecipitation, ChIP) and subsequent gene regulation would support the notion of a direct target. However, DNA binding is missing for the majority of the targets described for bone. Because ER and AR can bind to DNA in less than 1 h after ligand addition [Metivier et al., 2003] and mRNA increases of steroid responsive genes can be detected in as little as 1 h [Park et al., 2005], a direct target could be detectable in less than a few hours. A second category of direct targets contains those genes that are "late" direct targets. These genes are regulated directly by nuclear receptor binding at or near DNA later than the "early"

targets. Therefore, for this review, to include early and late genes, direct targets of the steroid hormone receptors will be defined as genes regulated by hormones in 24 h or less. Many studies have shown that these hormones can regulate, for example type 1 collagen in osteoblasts, after weeks of hormone treatment, but these could be indirect targets resulting from increased differentiation due to regulation of other direct hormone target genes. For this review, studies over-expressing ERs or AR in osteoblasts and studies using osteosarcoma cell lines or non-osteoblast cell lines have been omitted, although many of them provide valuable model systems.

DIRECT TARGETS OF E2 IN OSTEOBLASTS

In Table I the genes that are possible direct targets of E2 in osteoblasts are listed. They have been shown to be upregulated by E2 in 24 h or less.

Denger et al. [2008] identified 46 genes that were direct targets of E2 in primary human osteoblasts. Their microarray analysis included cycloheximide and ICI treatments of E2 treated osteoblasts to identify the direct ER targets. The majority of up-regulated genes were involved in signal transduction and regulation of transcription, and many of the down-regulated genes included immune and inflammatory response genes. They focused their work on the up-regulation of IGFBP4 by ERα. ERα was shown to bind to an intron of IGFBP4. IGF-1 and -II, which bind to, and are regulated by, IGFBP4, regulate osteoblast proliferation, differentiation and activity.

Recent work from our lab has begun to elucidate the mechanism underlying E2-induced apoptosis in osteoclasts [Krum and Brown, 2008; Krum et al., 2008a]. We showed that E2, via ERα, induces transcription of Fas Ligand (FasL) in osteoblasts, resulting in a paracrine signal that induces osteoclast apoptosis. Our data contradicts the work of Nakamura et al. [2007] where it is suggested that FasL is transcriptionally induced by E2 in *osteoclasts*. Nakamura et al. used an ERα specific knockout in osteoclasts (ERα$^{\Delta OC/\Delta OC}$) and showed a lack of regulation of FasL expression in ERα$^{\Delta OC/\Delta OC}$ mice. However, this work did not examine the localization of FasL in either osteoblasts or osteoclasts, as they used whole bones instead of purified cell types in their assays. In contrast, we showed that E2 induces FasL in primary calvarial osteoblasts and an osteoblast cell line (MC3T3, which is a calvarial-derived osteoblast cell line). In vivo, E2 induces FasL expression in osteoblasts but not in osteoclasts, as demonstrated by co-localization with RUNX2; FasL is detected at the growth plate and endosteal surface of mouse

femurs, but not in osteoclasts at either location. In addition, antibody-purified osteoclasts do not undergo E2-induced apoptosis unless osteoblasts are added in a co-culture system. Finally, co-cultures of MC3T3 osteoblasts and ERαKO bone marrow-derived osteoclasts demonstrate that ERα in *osteoblasts* is necessary and sufficient for osteoclast apoptosis. Together these experiments support our model that E2 induces FasL in osteoblasts to induce apoptosis of osteoclasts [Krum and Brown, 2008].

Alkaline phosphatase is a marker of early osteoblast differentiation and is important in the mineralization of bone. For years it has been shown that alkaline phosphatase is up-regulated in the presence of E2, as compared with a vehicle control [Scheven et al., 1992]. In mouse femurs, E2 upregulates alkaline phosphatase after 4–8 days, as detected by Northern blot [Plant and Tobias, 2001]. In primary calvarial osteoblasts alkaline phosphatase mRNA can be detected in 3 h by quantitative PCR [Krum et al., 2008b], and is thus a likely direct target of E2.

Receptor activator of nuclear factor κB ligand (RANKL) is an essential cytokine for osteoclastogenesis [Boyle et al., 2003]. RANKL is made in osteoblasts, marrow stromal cells and T-cells and binds to the RANK receptor on osteoclast progenitors [Boyle et al., 2003]. Binding of RANKL to the RANK receptor leads to activation of TNF receptor-associated factors (TRAFs) 1, 2, 3, 5, and 6 and subsequent NF-κB up-regulation of osteoclast target genes [Lee and Kim, 2003]. The RANKL pathway can be inhibited by osteoprotegerin (OPG), which acts as a decoy receptor for RANKL. Thus the RANKL:OPG ratio is critical for osteoclastogenesis. E2 has been shown to decrease the RANKL:OPG ratio in primary human osteoblast cells by increasing the amount of OPG [Bord et al., 2003] after 24 h of hormone treatment. Longer E2 treatments have revealed both repression of OPG [Cheung et al., 2003] and an increase in OPG [Chen et al., 2003].

Withdrawal of estrogens leads to apoptosis of both osteocytes and osteoblasts. Furthermore, E2 protects against DNA damage induced by drugs such as etoposide [Kousteni et al., 2002]. Pantschenko and colleagues demonstrated that E2 induces the anti-apoptotic protein Bcl-2 in ex vivo osteoblast cultures [Pantschenko et al., 2005]. Interestingly, the over-expression of Bcl-2 in osteoblasts results in loss of the sex differences between male and female bone turnover [Pantschenko et al., 2005]. Therefore, E2 induces Bcl-2 to prevent osteoblast and osteocyte apoptosis.

Not only does E2 inhibit apoptosis in osteoblasts, but it may decrease proliferation and/or increase differentiation (see above). Theses changes may be mediated through an increase in Rbbp1 (Retinoblastoma-binding protein 1) by E2 [Monroe et al., 2006].

TABLE I. E2 Targets in Osteoblasts

Target	Regulation	Time (h)	Cell type	References
FasL	⇑	3	Mouse calvarial osteoblasts	Krum et al. [2008a]
Alkaline phosphatase	⇑	3	Mouse calvarial osteoblasts	Krum et al. [2008b]
Bcl-2	⇑	24	Mouse calvarial osteoblasts	Pantschenko et al. [2005].
OPG	⇑	24	Primary human osteoblasts	Bord et al. [2003]
Rbbp1	⇑	4	Mouse calvarial osteoblasts	Monroe et al. [2006]
BMP-2	⇑	24	Mouse MSCs differentiated to OBs	Zhou et al. [2003]
IGFBP4	⇑	24	Primary human osteoblasts	Denger et al. [2008]
ERα	⇑	24	Primary human osteoblasts	Bord et al. [2003]
TGF-β3	⇑	2	Rat femora	Yang et al. [1996]

Rbbp1 has been shown to interact with Rb to decrease E2F1-mediated proliferation. Rb is also known to interact with Runx2 to increase osteoblast differentiation [Thomas et al., 2001]. E2 also increases osteoblast differentiation by up-regulating bone morphogenic protein 2 (BMP-2) after 24 h in murine osteoblasts [Zhou et al., 2003]. BMP-2 stimulates bone formation in vitro and in vivo. BMP-2 is a direct target of E2, as demonstrated by cycloheximide studies. This would suggest that an important role for E2 in osteoblast direct-gene regulation is the inhibition of proliferation and/or activation of differentiation-specific genes.

It has been suggested that E2 also regulates BMP-4 and BMP-6 in osteoblasts, although there is no data to suggest that these are direct targets of E2 in primary osteoblasts. BMP-4 is increased 1 week after ovariectomy [Min et al., 2007] and this data is supported by luciferase assays in the U2OS osteosarcoma cell line [van den Wijngaard et al., 2000]. In contrast, BMP-6 is up-regulated 8 days after E2 treatment of ovariectomized mice (but not after 1, 2, or 4 days) [Plant and Tobias, 2002] and in cell lines that over-express ERα [Rickard et al., 1998; Ong et al., 2004].

After ovariectomy TGF-β3 mRNA decreases in rat femora. In as little as 2 h after E2 treatment, TGF-β3 mRNA increases in the bone. In contrast, TGF-β1 and -β2 did not increase after E2 treatment. Raloxifene, being estrogenic in the bone, also increases TGF-β3 mRNA [Yang et al., 1996]. These studies used whole bones, but it is likely that the TGF-β3 is transcribed in osteoblasts. Reporter assays confirmed regulation in an osteoblast-like cell line (MG63). Thus, one mechanism of the protective effects of E2 is to increase TGF-β3, which inhibits osteoclast differentiation and bone resorption.

ERα is known to be regulated through transcriptional, post-transcriptional and translational mechanisms. Bord et al. [2003] demonstrated that E2 treatment increased ERα mRNA after 24 h and an increase in ERα protein after 48 h in primary human osteoblasts; earlier time points were not described. This is in contrast to a decrease in ERα mRNA and protein that is seen in the model E2-responsive cell line MCF7 cells [Pink and Jordan, 1996].

ERα VERSUS ERβ IN OSTEOBLASTS

Both ERα and ERβ are expressed in osteoblasts. However, we do not know if the genes described above are truly direct targets of ERα, ERβ or both because binding of a receptor to the DNA has not been shown for any of the genes. Chromatin immunoprecipitation of ERα or ERβ would answer this. A second way to demonstrate the role of ERα or ERβ in primary osteoblasts would be to use an ERα specific ligand such as PPT or an ERβ specific ligand such as DPN.

Rbbp1 is a target of E2 in primary osteoblasts (see above). Chromatin immunoprecipitation has shown that ERα and ERβ bind to intron 1 of Rbbp1 in U2OS cells over-expressing the receptor. However, ChIP has not been performed to prove that ERβ regulates Rbbp1 in primary osteoblasts.

DIRECT TARGETS OF E2 IN OSTEOCLASTS

Oursler et al. [1991] treated avian osteoclasts for 30 min with E2 and saw increases in c-fos and c-jun mRNA (Table II). C-fos and c-jun are members of the AP-1 family of transcription factors. C-fos has an important role in osteoclast differentiation; mice lacking c-fos do not have osteoclasts and are osteopetrotic. E2 signals through AP-1 family members, and E2 up-regulation of c-fos and c-jun may amplify the E2 signal.

E2 decreases the osteoclastic resorption pit in bone. This effect is mediated by E2 decreasing secretion of cathepsin B, cathepsin L, cathepsin K and TRAP [Kremer et al., 1995; Mano et al., 1996] into the acidic extracellular compartment responsible for eroding bone. Each of these enzymes is potentially a direct target of E2 as the proteins are down-regulated in less than 24 h. Cathepsin K was confirmed to be a direct target with transcription and translation inhibitors. In the presence of cycloheximide there was still a decrease in cathepsin K mRNA, but not with the transcription inhibitor actinomycin D.

Interleukin-1 is a pro-inflammatory cytokine that is capable of inducing osteoclast formation from precursor cells. Not only is IL-1 repressed by E2 in immune cells, but the IL-1 receptor (IL-1R) is repressed by E2 in osteoclasts. Furthermore, the decoy receptor IL-1RII is increased by E2. Together, the osteoclastogenic IL-1 signaling is decreased by E2 [Sunyer et al., 1999].

Nakamura et al. used an ERα specific knockout in osteoclasts (ERα$^{\Delta OC/\Delta OC}$) and show a lack of regulation of FasL expression in ERα$^{\Delta OC/\Delta OC}$ mice. However, this work did not examine the localization of FasL in either osteoblasts or osteoclasts, as they used whole bones instead of purified cell types in their immunoblot and microarray analyses [Nakamura et al., 2007] (see FasL regulation in osteoblasts, above). Furthermore, we and others have not detected an increase in FasL in wildtype osteoclasts [Krum et al., 2008a; Martin-Millan et al., 2010].

In summary, there are several known E2 targets in osteoclasts. Microarray analysis of wildtype osteoclasts treated with E2 for a short time period (i.e., 3 h), or osteoclasts from ERαKO mice or osteoclast specific-ERαKO mice may reveal additional potential targets of ERα. However, any differentially regulated genes must be analyzed to be direct or indirect targets of estrogens.

TABLE II. E2 Targets in Osteoclasts

Target	Regulation	Time	Cell type	References
c-fos and c-jun	⇑	30 min	Avian osteoclasts	Oursler et al. [1991]
Cathepsin K	⇓	3 h	Rabbit osteoclasts	Mano et al. [1996]
TRAP, Cathepsins B, L, K	⇓ (secreted proteins)	18 h	Avian osteoclasts	Kremer et al. [1995]
IL-1RI	⇓	4 h	Human osteoclasts	Sunyer et al. [1999]
IL-1RII	⇑	4 h	Human osteoclasts	Sunyer et al. [1999]

TABLE III. Androgen Targets in Osteoblasts

Target	Regulation	Time (h)	Cell type	References
Mybl2, Hoxd11, ADCYAP1R1	⇑	12	Human fetal osteoblasts	Miki et al. [2007]
TGF-β	⇑	10	Mouse calvarial osteoblasts	Kasperk et al. [1990]

EFFECTS OF ANDROGENS IN BONE

Androgens affect the skeleton in both men and women. Androgen deficiency is associated with low bone mineral density [Finkelstein et al., 1987], partly through loss of muscle mass, which decreases mechanical strain and bone mineral density. It was previously thought that testosterone effected bone largely via aromatization to estrogen [Compston, 2001]. However, we now know that androgens have a direct effect through the androgen receptor in bone. AR is expressed in both osteoblasts and osteoclasts [Vanderschueren et al., 2004]. The few known direct targets of AR in these cell types are described below and listed in Tables III and IV.

Androgens have been shown to increase osteoblast proliferation in mouse and human primary osteoblasts [Kasperk et al., 1989]. Furthermore, DHT, a non-aromatizable form of testosterone, has been shown to increase proliferation of MC3T3-E1 calvarial osteoblasts in a dose dependent fashion that signals through both AR and the PI3-kinase/AKT pathway [Kang et al., 2004].

In addition to increasing osteoblast proliferation, androgens, like estrogens, inhibit osteoblast apoptosis. Osteoblast apoptosis, induced by a number of stimuli, can be prevented with DHT [Kousteni et al., 2001]. Furthermore, orchidectomy of mice increases osteoblast apoptosis in vivo [Kousteni et al., 2001]. These protective effects of androgens are mediated through rapid activation of both AR and the Src/Shc/ERK signaling pathways, as opposed to classical AR activation of transcription.

Like estrogens, androgens' effect on bone may also be indirectly mediated by regulation of cytokines from immune cells and/or stromal cells/osteoblasts that are important for osteoclastogenesis. For example, men treated with a GNRH antagonist and an aromatase inhibitor (to prevent the enzyme aromatase from converting testosterone to estrogen) had more of the osteoclastogenic cytokine TNFα in the serum than men treated with replacement testosterone [Khosla et al., 2002].

GENETIC MODELS OF ANDROGENS IN BONE

AR knockout (AndRKO) mice have increased bone resorption leading to reduced trabecular and cortical bone mass [Kawano et al., 2003], indicating the importance of androgen action through AR and not through aromatization to estrogen. However, these results are difficult to interpret due to low levels of testosterone and estradiol in these mice.

Testicular feminization male (TFM) rats are unresponsive to androgens due to a single base mutation in the ligand binding domain of AR. These rats have increased estradiol levels and the bone structures are more "female-like" in shape. The rats do not have a decrease in trabecular bone, as do orchidectomized rats, but do lose bone after orchidectomy [Vanderschueren et al., 1994].

Aromatase knockout (AromKO) mice have decreased cortical and cancellous bone in both female and male mice [Miyaura et al., 2001]. When these mice were treated with E2 the bone mass was completely restored in both sexes. The AromKO mice have a similar phenotype as described in a case study of a man with a point mutation in the aromatase gene. Unlike the men with point mutations in ERα, the man with the aromatase mutation had increased bone mineral density when treated with E2 [Bilezikian et al., 1998].

DIRECT TARGETS OF ANDROGENS IN OSTEOBLASTS

Microarray analysis of human fetal osteoblasts (hFOB) revealed 430 genes regulated by 10 nM DHT for 12 h [Miki et al., 2007] (Table III). Of these, MYBL2, HOXD11 and ADCYAP1R1 were validated in qPCR assays. MYBL2 regulates cell cycle and proliferation [Joaquin and Watson, 2003]. Interestingly, the DHT-mediated increase in MYBL2 mRNA was not blocked by the AR inhibitor hydroxyflutamide, suggesting that it is not a direct target of AR. HOXD11 is a homeobox gene that encodes for a protein involved in the development of the limbs and cortical bone formation [Villavicencio-Lorini et al., 2010]. ADCYAP1R1 encodes for a type I adenylate cyclase activating polypeptide receptor, and its role in bone or its activity in response to androgens are unknown.

Orchidectomy of mice reduces skeletal TGF-β by over 80% [Gill et al., 1998] and in vitro studies have shown that TGF-β is likely a direct target of androgens [Kasperk et al., 1990; Gill et al., 1998]. In as little as 10 h, TGF-β protein is induced by androgens in vitro in mouse calvarial osteoblasts [Kasperk et al., 1990], suggesting a direct regulation by androgens. TGF-β1 stimulates osteoblast proliferation of early osteoblastic precursor cells [Janssens et al., 2005], and thus androgens stimulate osteoblast proliferation, at least partly, through up-regulation of TGF-β.

TABLE IV. Androgen Targets in Osteoclasts

Target	Regulation	Time (h)	Cell type	References
TGF-β	⇑	24	Avian osteoclasts	Pederson et al. [1999]
Cathepsin B and TRAP	⇓	24	Avian osteoclasts	Pederson et al. [1999]

The literature suggests that androgens regulate OPG and IL6 in osteoblasts, as do estrogens. However, there is no evidence that these are direct AR targets in normal osteoblasts. Whereas E2 has been shown to up-regulate OPG, OPG mRNA and protein were shown to be repressed by androgen in an osteoblast cell line over-expressing AR [Hofbauer et al., 2002]. IL-6 induces osteoclastogenesis and may be repressed by androgens in osteoblasts, bone marrow stromal cells or another cell in the bone marrow. Orchidectomy increases IL-6 levels in the serum of mice 3 days after surgery and IL-6 in the bone marrow 28 days after surgery [Zhang et al., 1998]. IL-6 mice do not lose bone mass after orchidectomy [Bellido et al., 1995]. In vitro, androgens repress IL-6 secretion from bone marrow stromal cells and from hFOB/AR-6 cells (hFOB cells over-expressing the androgen receptor) [Bellido et al., 1995; Hofbauer et al., 1999]. Thus, it is likely that IL-6 is a direct target of androgens in osteoblasts, but additional experiments need to be performed.

DIRECT TARGETS OF ANDROGENS IN OSTEOCLASTS

While E2 inhibits osteoclast formation through induction of FasL in osteoblasts [Krum et al., 2008a], androgens decrease osteoclastogenesis by a distinct, yet unknown, mechanism than E2 [Michael et al., 2005] (Table IV). Testosterone has a direct inhibitory effect on osteoclast formation. CD14+ human monocytes, differentiated to osteoclasts, do not form as many TRAP+ osteoclasts when treated with testosterone, whereas E2 has no effect in the absence of osteoblasts [Michael et al., 2005; Krum et al., 2008a].

Very few studies describe the direct targets of androgens in osteoclasts. Pederson et al. [1999] treated avian osteoclasts with DHT and saw an increase in TGF-β and decreases in cathepsin B and TRAP protein 24 h after treatment. TGF-β1 inhibits osteoclastogenesis under some conditions while stimulating osteoclast formation and resorption under other in vitro conditions [Janssens et al., 2005]. Although Cathepsin K is the major cathepsin expressed in osteoclasts, cathepsin B also is expressed and found in resorption pits [Goto et al., 1994]. Thus, the decrease in resorptive activity of osteoclasts treated with DHT can be explained by the repression of TRAP and cathepsin B. The genes involved in androgen-mediated apoptosis of osteoclasts remain to be identified.

SUMMARY

We know relatively little about the direct targets of sex steroid hormones in bone. Microarray analysis has been under-utilized to determine the genes regulated by estrogens and androgens. Technology such as ChIP-sequencing makes it possible to analyze all of the direct genomic targets of ERs and AR in primary cells. Knowing all of the targets of sex steroid hormones in bone cells will facilitate the development of tissue-specific ligands (selective estrogen receptor modulators (SERMs) or selective androgen receptor modulators (SARMs)) for treatment or prevention of osteoporosis.

REFERENCES

Albright F, Bloomberg E, Smith PH. 1940. Postmenopausal osteoporosis. Trans Assoc Am Physicians 55:298–305.

Bellido T, Jilka RL, Boyce BF, Girasole G, Broxmeyer H, Dalrymple SA, Murray R, Manolagas SC. 1995. Regulation of interleukin-6, osteoclastogenesis, and bone mass by androgens. The role of the androgen receptor. J Clin Invest 95:2886–2895.

Bilezikian JP, Morishima A, Bell J, Grumbach MM. 1998. Increased bone mass as a result of estrogen therapy in a man with aromatase deficiency. N Engl J Med 339:599–603.

Bord S, Horner A, Beavan S, Compston J. 2001. Estrogen receptors alpha and beta are differentially expressed in developing human bone. J Clin Endocrinol Metab 86:2309–2314.

Bord S, Ireland DC, Beavan SR, Compston JE. 2003. The effects of estrogen on osteoprotegerin, RANKL, and estrogen receptor expression in human osteoblasts. Bone 32:136–141.

Boyle WJ, Simonet WS, Lacey DL. 2003. Osteoclast differentiation and activation. Nature 423:337–342.

Braidman IP, Hainey L, Batra G, Selby PL, Saunders PT, Hoyland JA. 2001. Localization of estrogen receptor beta protein expression in adult human bone. J Bone Miner Res 16:214–220.

Castro-Rivera E, Samudio I, Safe S. 2001. Estrogen regulation of cyclin D1 gene expression in ZR-75 breast cancer cells involves multiple enhancer elements. J Biol Chem 276:30853–30861.

Chen X, Garner SC, Quarles LD, Anderson JJ. 2003. Effects of genistein on expression of bone markers during MC3T3-E1 osteoblastic cell differentiation. J Nutr Biochem 14:342–349.

Cheung J, Mak YT, Papaioannou S, Evans BA, Fogelman I, Hampson G. 2003. Interleukin-6 (IL-6), IL-1, receptor activator of nuclear factor kappaB ligand (RANKL) and osteoprotegerin production by human osteoblastic cells: Comparison of the effects of 17-beta oestradiol and raloxifene. J Endocrinol 177:423–433.

Compston JE. 2001. Sex steroids and bone. Physiol Rev 81:419–447.

Denger S, Bahr-Ivacevic T, Brand H, Reid G, Blake J, Seifert M, Lin CY, May K, Benes V, Liu ET, Gannon F. 2008. Transcriptome profiling of estrogen-regulated genes in human primary osteoblasts reveals an osteoblast-specific regulation of the insulin-like growth factor binding protein 4 gene. Mol Endocrinol 22:361–379.

Finkelstein JS, Klibanski A, Neer RM, Greenspan SL, Rosenthal DI, Crowley WF, Jr. 1987. Osteoporosis in men with idiopathic hypogonadotropic hypogonadism. Ann Intern Med 106:354–361.

Foradori CD, Weiser MJ, Handa RJ. 2008. Non-genomic actions of androgens. Front Neuroendocrinol 29:169–181.

Gill RK, Turner RT, Wronski TJ, Bell NH. 1998. Orchiectomy markedly reduces the concentration of the three isoforms of transforming growth factor beta in rat bone and reduction is prevented by testosterone. Endocrinology 139:546–550.

Goto T, Kiyoshima T, Moroi R, Tsukuba T, Nishimura Y, Himeno M, Yamamoto K, Tanaka T. 1994. Localization of cathepsins B, D, and L in the rat osteoclast by immuno-light and -electron microscopy. Histochemistry 101:33–40.

Hewitt SC, Collins J, Grissom S, Hamilton K, Korach KS. 2006. Estren behaves as a weak estrogen rather than a nongenomic selective activator in the mouse uterus. Endocrinology 147:2203–2214.

Hofbauer LC, Ten RM, Khosla S. 1999. The anti-androgen hydroxyflutamide and androgens inhibit interleukin-6 production by an androgen-responsive human osteoblastic cell line. J Bone Miner Res 14:1330–1337.

Hofbauer LC, Hicok KC, Chen D, Khosla S. 2002. Regulation of osteoprotegerin production by androgens and anti-androgens in human osteoblastic lineage cells. Eur J Endocrinol 147:269–273.

Janssens K, ten Dijke P, Janssens S, Van Hul W. 2005. Transforming growth factor-beta1 to the bone. Endocr Rev 26:743–774.

Jilka RL, Takahashi K, Munshi M, Williams DC, Roberson PK, Manolagas SC. 1998. Loss of estrogen upregulates osteoblastogenesis in the murine bone marrow. Evidence for autonomy from factors released during bone resorption. J Clin Invest 101:1942–1950.

Joaquin M, Watson RJ. 2003. Cell cycle regulation by the B-Myb transcription factor. Cell Mol Life Sci 60:2389–2401.

Kameda T, Mano H, Yuasa T, Mori Y, Miyazawa K, Shiokawa M, Nakamaru Y, Hiroi E, Hiura K, Kameda A, Yang NN, Hakeda Y, Kumegawa M. 1997. Estrogen inhibits bone resorption by directly inducing apoptosis of the bone-resorbing osteoclasts. J Exp Med 186:489–495.

Kang HY, Cho CL, Huang KL, Wang JC, Hu YC, Lin HK, Chang C, Huang KE. 2004. Nongenomic androgen activation of phosphatidylinositol 3-kinase/Akt signaling pathway in MC3T3-E1 osteoblasts. J Bone Miner Res 19:1181–1190.

Kasperk CH, Wergedal JE, Farley JR, Linkhart TA, Turner RT, Baylink DJ. 1989. Androgens directly stimulate proliferation of bone cells in vitro. Endocrinology 124:1576–1578.

Kasperk C, Fitzsimmons R, Strong D, Mohan S, Jennings J, Wergedal J, Baylink D. 1990. Studies of the mechanism by which androgens enhance mitogenesis and differentiation in bone cells. J Clin Endocrinol Metab 71:1322–1329.

Kawano H, Sato T, Yamada T, Matsumoto T, Sekine K, Watanabe T, Nakamura T, Fukuda T, Yoshimura K, Yoshizawa T, Aihara K, Yamamoto Y, Nakamichi Y, Metzger D, Chambon P, Nakamura K, Kawaguchi H, Kato S. 2003. Suppressive function of androgen receptor in bone resorption. Proc Natl Acad Sci USA 100:9416–9421.

Keeting PE, Scott RE, Colvard DS, Han IK, Spelsberg TC, Riggs BL. 1991. Lack of a direct effect of estrogen on proliferation and differentiation of normal human osteoblast-like cells. J Bone Miner Res 6:297–304.

Khosla S, Atkinson EJ, Dunstan CR, O'Fallon WM. 2002. Effect of estrogen versus testosterone on circulating osteoprotegerin and other cytokine levels in normal elderly men. J Clin Endocrinol Metab 87:1550–1554.

Kousteni S, Bellido T, Plotkin LI, O'Brien CA, Bodenner DL, Han L, Han K, DiGregorio GB, Katzenellenbogen JA, Katzenellenbogen BS, Roberson PK, Weinstein RS, Jilka RL, Manolagas SC. 2001. Nongenotropic, sex-nonspecific signaling through the estrogen or androgen receptors: Dissociation from transcriptional activity. Cell 104:719–730.

Kousteni S, Chen JR, Bellido T, Han L, Ali AA, O'Brien CA, Plotkin L, Fu Q, Mancino AT, Wen Y, Vertino AM, Powers CC, Stewart SA, Ebert R, Parfitt AM, Weinstein RS, Jilka RL, Manolagas SC. 2002. Reversal of bone loss in mice by nongenotropic signaling of sex steroids. Science 298:843–846.

Kremer M, Judd J, Rifkin B, Auszmann J, Oursler MJ. 1995. Estrogen modulation of osteoclast lysosomal enzyme secretion. J Cell Biochem 57:271–279.

Krum SA, Brown M. 2008. Unraveling estrogen action in osteoporosis. Cell Cycle 7:1348–1352.

Krum SA, Miranda-Carboni GA, Hauschka PV, Carroll JS, Lane TF, Freedman LP, Brown M. 2008a. Estrogen protects bone by inducing Fas ligand in osteoblasts to regulate osteoclast survival. EMBO J 27:535–545.

Krum SA, Miranda-Carboni GA, Lupien M, Eeckhoute J, Carroll JS, Brown M. 2008b. Unique ER{alpha} cistromes control cell type-specific gene regulation. Mol Endocrinol 22:2393–2406.

Lee ZH, Kim HH. 2003. Signal transduction by receptor activator of nuclear factor kappa B in osteoclasts. Biochem Biophys Res Commun 305:211–214.

Levin ER. 2005. Integration of the extranuclear and nuclear actions of estrogen. Mol Endocrinol 19:1951–1959.

Mano H, Yuasa T, Kameda T, Miyazawa K, Nakamaru Y, Shiokawa M, Mori Y, Yamada T, Miyata K, Shindo H, Azuma H, Hakeda Y, Kumegawa M. 1996. Mammalian mature osteoclasts as estrogen target cells. Biochem Biophys Res Commun 223:637–642.

Martin-Millan M, Almeida M, Ambrogini E, Han L, Zhao H, Weinstein RS, Jilka RL, O'Brien CA, Manolagas SC. 2010. The estrogen receptor-alpha in osteoclasts mediates the protective effects of estrogens on cancellous but not cortical bone. Mol Endocrinol 24:323–334.

Metivier R, Penot G, Hubner MR, Reid G, Brand H, Kos M, Gannon F. 2003. Estrogen receptor-alpha directs ordered, cyclical, and combinatorial recruitment of cofactors on a natural target promoter. Cell 115:751–763.

Michael H, Harkonen PL, Vaananen HK, Hentunen TA. 2005. Estrogen and testosterone use different cellular pathways to inhibit osteoclastogenesis and bone resorption. J Bone Miner Res 20:2224–2232.

Miki Y, Suzuki T, Hatori M, Igarashi K, Aisaki KI, Kanno J, Nakamura Y, Uzuki M, Sawai T, Sasano H. 2007. Effects of aromatase inhibitors on human osteoblast and osteoblast-like cells: A possible androgenic bone protective effects induced by exemestane. Bone 40:876–887.

Min HJ, Lee MJ, Kim JY, Cho SW, Park HD, Lee SI, Kim HJ, Jung HS. 2007. Alteration of BMP-4 and Runx2 expression patterns in mouse temporomandibular joint after ovariectomy. Oral Dis 13:220–227.

Miyaura C, Toda K, Inada M, Ohshiba T, Matsumoto C, Okada T, Ito M, Shizuta Y, Ito A. 2001. Sex- and age-related response to aromatase deficiency in bone. Biochem Biophys Res Commun 280:1062–1068.

Monroe DG, Secreto FJ, Hawse JR, Subramaniam M, Khosla S, Spelsberg TC. 2006. Estrogen receptor isoform-specific regulation of the retinoblastoma-binding protein 1 (RBBP1) gene: Roles of AF1 and enhancer elements. J Biol Chem 281:28596–28604.

Nakamura T, Imai Y, Matsumoto T, Sato S, Takeuchi K, Igarashi K, Harada Y, Azuma Y, Krust A, Yamamoto Y, Nishina H, Takeda S, Takayanagi H, Metzger D, Kanno J, Takaoka K, Martin TJ, Chambon P, Kato S. 2007. Estrogen prevents bone loss via estrogen receptor alpha and induction of Fas ligand in osteoclasts. Cell 130:811–823.

Ong DB, Colley SM, Norman MR, Kitazawa S, Tobias JH. 2004. Transcriptional regulation of a BMP-6 promoter by estrogen receptor alpha. J Bone Miner Res 19:447–454.

Oursler MJ, Osdoby P, Pyfferoen J, Riggs BL, Spelsberg TC. 1991. Avian osteoclasts as estrogen target cells. Proc Natl Acad Sci USA 88:6613–6617.

Pantschenko AG, Zhang W, Nahounou M, McCarthy MB, Stover ML, Lichtler AC, Clark SH, Gronowicz GA. 2005. Effect of osteoblast-targeted expression of bcl-2 in bone: Differential response in male and female mice. J Bone Miner Res 20:1414–1429.

Park SE, Xu J, Frolova A, Liao L, O'Malley BW, Katzenellenbogen BS. 2005. Genetic deletion of the repressor of estrogen receptor activity (REA) enhances the response to estrogen in target tissues in vivo. Mol Cell Biol 25:1989–1999.

Pederson L, Kremer M, Judd J, Pascoe D, Spelsberg TC, Riggs BL, Oursler MJ. 1999. Androgens regulate bone resorption activity of isolated osteoclasts in vitro. Proc Natl Acad Sci USA 96:505–510.

Pink JJ, Jordan VC. 1996. Models of estrogen receptor regulation by estrogens and antiestrogens in breast cancer cell lines. Cancer Res 56:2321–2330.

Plant A, Tobias JH. 2001. Characterisation of the temporal sequence of osteoblast gene expression during estrogen-induced osteogenesis in female mice. J Cell Biochem 82:683–691.

Plant A, Tobias JH. 2002. Increased bone morphogenetic protein-6 expression in mouse long bones after estrogen administration. J Bone Miner Res 17:782–790.

Revankar CM, Cimino DF, Sklar LA, Arterburn JB, Prossnitz ER. 2005. A transmembrane intracellular estrogen receptor mediates rapid cell signaling. Science 307:1625–1630.

Rickard DJ, Hofbauer LC, Bonde SK, Gori F, Spelsberg TC, Riggs BL. 1998. Bone morphogenetic protein-6 production in human osteoblastic cell lines. Selective regulation by estrogen. J Clin Invest 101:413–422.

Riggs BL. 2000. The mechanisms of estrogen regulation of bone resorption. J Clin Invest 106:1203–1204.

Robinson JA, Harris SA, Riggs BL, Spelsberg TC. 1997. Estrogen regulation of human osteoblastic cell proliferation and differentiation. Endocrinology 138:2919–2927.

Scheven BA, Damen CA, Hamilton NJ, Verhaar HJ, Duursma SA. 1992. Stimulatory effects of estrogen and progesterone on proliferation and differentiation of normal human osteoblast-like cells in vitro. Biochem Biophys Res Commun 186:54–60.

Smith EP, Boyd J, Frank GR, Takahashi H, Cohen RM, Specker B, Williams TC, Lubahn DB, Korach KS. 1994. Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. N Engl J Med 331:1056–1061.

Sunyer T, Lewis J, Collin-Osdoby P, Osdoby P. 1999. Estrogen's bone-protective effects may involve differential IL-1 receptor regulation in human osteoclast-like cells. J Clin Invest 103:1409–1418.

Syed FA, Modder UI, Fraser DG, Spelsberg TC, Rosen CJ, Krust A, Chambon P, Jameson JL, Khosla S. 2005. Skeletal effects of estrogen are mediated by opposing actions of classical and nonclassical estrogen receptor pathways. J Bone Miner Res 20:1992–2001.

Thomas DM, Carty SA, Piscopo DM, Lee JS, Wang WF, Forrester WC, Hinds PW. 2001. The retinoblastoma protein acts as a transcriptional coactivator required for osteogenic differentiation. Mol Cell 8:303–316.

van den Wijngaard A, Mulder WR, Dijkema R, Boersma CJ, Mosselman S, van Zoelen EJ, Olijve W. 2000. Antiestrogens specifically up-regulate bone morphogenetic protein-4 promoter activity in human osteoblastic cells. Mol Endocrinol 14:623–633.

Vanderschueren D, Van Herck E, Geusens P, Suiker A, Visser W, Chung K, Bouillon R. 1994. Androgen resistance and deficiency have different effects on the growing skeleton of the rat. Calcif Tissue Int 55:198–203.

Vanderschueren D, Vandenput L, Boonen S, Lindberg MK, Bouillon R, Ohlsson C. 2004. Androgens and bone. Endocr Rev 25:389–425.

Verrijdt G, Haelens A, Claessens F. 2003. Selective DNA recognition by the androgen receptor as a mechanism for hormone-specific regulation of gene expression. Mol Genet Metab 78:175–185.

Villavicencio-Lorini P, Kuss P, Friedrich J, Haupt J, Farooq M, Turkmen S, Duboule D, Hecht J, Mundlos S. 2010. Homeobox genes d11-d13 and a13 control mouse autopod cortical bone and joint formation. J Clin Invest 120:1994–2004.

Weitzmann MN, Pacifici R. 2006. Estrogen regulation of immune cell bone interactions. Ann N Y Acad Sci 1068:256–274.

Windahl SH, Andersson G, Gustafsson JA. 2002. Elucidation of estrogen receptor function in bone with the use of mouse models. Trends Endocrinol Metab 13:195–200.

Yang NN, Bryant HU, Hardikar S, Sato M, Galvin RJ, Glasebrook AL, Termine JD. 1996. Estrogen and raloxifene stimulate transforming growth factor-beta 3 gene expression in rat bone: A potential mechanism for estrogen- or raloxifene-mediated bone maintenance. Endocrinology 137:2075–2084.

Zhang J, Pugh TD, Stebler B, Ershler WB, Keller ET. 1998. Orchiectomy increases bone marrow interleukin-6 levels in mice. Calcif Tissue Int 62:219–226.

Zhou S, Turgeman G, Harris SE, Leitman DC, Komm BS, Bodine PV, Gazit D. 2003. Estrogens activate bone morphogenetic protein-2 gene transcription in mouse mesenchymal stem cells. Mol Endocrinol 17:56–66.